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Abstract: Molecular characterization is increasingly changing clinical practice, in both 
diagnosis and treatment. BRAF is a proto-oncogene that is mutated in ~2%–4% of lung cancers, 
but the incidence rises to 40%–45% among papillary thyroid cancers. Furthermore, BRAF 
is a promising target in lung cancer treatment. The present case study covers both the chal-
lenges of molecular differential diagnosis and the perspectives opened by targeted therapy by 
discussing the history of a 78-year-old female affected by a papillary histotype carcinoma with 
BRAF mutation associated with both thyroid and lung localizations. A differential diagnosis 
was possible as a consequence of a multidisciplinary approach including an in-depth molecular 
characterization. Based on this molecular feature, the patient was successfully treated with the 
BRAF inhibitor dabrafenib after the failure of treatment with standard regimen. To the best of 
our knowledge, this is the first published case of non-small-cell lung cancer with metastasis to 
thyroid and with BRAF V600E mutation.
Keywords: BRAF mutation, molecular diagnosis, target therapy
Introduction
BRAF is a proto-oncogene that has been found to be mutated in a wide range of tumors, 
including colorectal cancer, malignant melanoma, papillary thyroid carcinoma, and 
less frequently lung adenocarcinoma.1–8
Cancer metastasization to the thyroid gland is a rare event, with an incidence ranging 
from 0.1%–3% in clinical series, and from 4.4%–24% in autopsy studies.9–11 The primary 
tumors that most frequently metastasize to the thyroid gland are renal cell (48.1%), 
colorectal (10.4%), lung (8.3%), and breast (7.8%) cancers; melanoma (4%); sarcoma 
(4%);12 and other types (17.4%).9–11 Recently, a Phase II Basket Study assessing the role 
of a BRAF inhibitor in BRAF V600-mutated nonmelanoma cancers showed a meaningful 
activity in non-small-cell lung cancers (NSCLCs).13
We herein report the case of a patient who underwent thyroidectomy for a cytologi-
cal suspicion of thyroid cancer, which had been proven to be due to the metastasis of 
a BRAF-mutated adenocarcinoma of the lung. To the best of our knowledge, this is 
the first reported case of NSCLC with BRAF V600E mutation that metastasized to 
the thyroid gland.14–19 Based on this molecular feature, the patient was successfully 
treated with the BRAF inhibitor dabrafenib.
Case presentation
A 78-year-old female with a medical history of arterial hypertension, hypercholes-
terolemia, and lumbar disc herniations complained of lower back pain, occasional 
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dry cough, and slight weight loss in the previous month 
(,5%). Subsequent investigations included a thyroid fine-
needle aspiration biopsy (FNAB) which was suspicious for 
malignant lesion. At the time of biopsy, the patient was on 
the following medications: bisoprolol, lisinopril, and hydro-
chlorothiazide. Social history was positive for passive and 
active smoking (five cigarettes per day for 5 years).
FNAB showed micropapillary nests with cytological atypia 
interpreted as atypical papillary proliferation of the thyroid 
(Tyr-4). Five months later, she underwent surgical resection 
of the thyroid lesion, and the histology report confirmed 
the diagnosis of thyroid papillary carcinoma (galectin-3/
cytokeratin 19/HBME-1 positive and TPO negative).
Staging magnetic resonance imaging scan of the spine, 
performed just before thyroidectomy, showed osteoblastic 
lesions in lumbar vertebral bodies and sacrum. A computed 
tomography (CT) scan performed 1 month later detected left 
pulmonary hilum and lower lobe metastases with massive 
mediastinal involvement. In particular, an infiltration of the 
superior lobar artery and the inferior pulmonary vein, as well 
as a compression of both principal and apical bronchi were 
observed. The upper-left segment was significantly impaired by 
lymphangitic carcinomatosis, and the lower lobe was partially 
atelectatic. Keeping in view the advanced stage of the disease 
and the clinical implications associated with thoracic involve-
ment, radiometabolic treatment with iodine (I-131) was omitted 
to give priority to the management of lung lesions. The paper 
was published after obtaining the patient’s written consent.
Investigations
A bronchoscopy with cytohistological sampling was performed, 
and a bone scan confirmed widespread metastatic involve-
ment of the bone. Morphological and immunohistochemical 
assessments by both transbronchial needle aspiration and 
transbronchial biopsy were consistent with the diagnosis of 
lung adenocarcinoma with micropapillary features, napsin 
A/TTF1/cytokeratin 7 positive and HTG negative.
According to College of American Pathologists/Interna-
tional Association for the Study of Lung Cancer/Association 
for Molecular Pathology guidelines, molecular testing was 
also conducted.20 We used a multigene panel with a mass 
spectrometry technique, matrix-assisted laser desorption 
ionization-time of flight (Agena Bioscience, Inc., San Diego, 
CA, USA), which simultaneously analyzes EGFR, KRAS, 
BRAF, and PIK3CA.
To rule out the possibility of a thyroid cancer metasta-
sizing to the lung, immunohistochemistry analyses were 
performed on both lung and thyroid tumor specimens, and 
the results showed a concordant immunophenotype in both 
the lesions: PAX8/HTG negative and cytokeratin 7/napsin 
A/TTF1 positive. 
Overall, morphological, immunohistochemical, and 
molecular features supported the diagnosis of adenocarci-
noma of the lung, presence of BRAF V600E mutations, and 
metastasis to the thyroid gland (Figure 1). 
Differential diagnosis
Based on the unusual clinical presentation, differential 
diagnosis was to be made between advanced thyroid car-
cinoma, lung carcinoma, and cancer of unknown primary. 
The pathologic and molecular revision of the thyroid speci-
men led to the diagnosis of metastatic involvement of lung 
adenocarcinoma.
Treatment
The patient underwent a first-line treatment with a combina-
tion of carboplatin, at an area under the curve of 5 (equal to 
360 mg), and pemetrexed 500 mg/m2, with an age-related dose 
reduction of 25%. Both drugs were administered intravenously 
once every 21 days. The patient received premedication with 
dexamethasone, vitamin B12, and folic acid according to 
pemetrexed label. Single-agent pemetrexed was planned after 
four cycles of combination chemotherapy. Restaging whole-
body CT scan performed after four cycles of treatment showed 
progression of the disease, leading to the discontinuation of 
the first-line chemotherapy, with a progression-free survival 
of 2.5 months. At this time point, the performance status of the 
patient was 1 according to the Eastern Cooperative Oncology 
Group classification, and a second-line treatment was there-
fore considered.21 According to NCCN Guidelines, possible 
options included docetaxel or erlotinib.22 However, based on 
the mutational status and according to the results reported in 
the literature,15,23,24 we proposed a target-driven therapy with 
a BRAF inhibitor subject to an off-label approval. Dabrafenib 
150 mg twice daily (every 12 hours) was started; zoledronic 
acid was also initiated.
Outcome and follow-up
After 2 months, the best response to carboplatin/pemetrexed 
was stable disease. Treatment was fairly well tolerated, with 
G2 nausea for 2 days following each administration. After 
four cycles, however, CT scan showed disease progression 
without clinical deterioration. The second-line treatment 
with dabrafenib was very well tolerated with the patient 
experiencing only a mild skin toxicity, mainly xerosis and 
pruritus. The first tumor assessment, performed after 2 months 
of treatment, showed stable disease, with some of the lung 
lesions shrinking but with persistence of lung hypoexpansion 
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and lymphangitic carcinomatosis of the lower-left lobe. 
The second tumor assessment planned after 4 months of 
dabrafenib showed a further improvement, achieving a 
partial response according to Response Evaluation Criteria 
In Solid Tumors criteria, with a significant reduction of the 
interstitial involvement as well as a partial resolution of the 
atelectasis (Figure 2).
Discussion
The thyroid gland is an uncommon site of metastatic involve-
ment and most of the thyroid tumors are of primary origin.25 
The incidence of secondary neoplasms of the thyroid, akin to 
papillary thyroid microcarcinomas, is expected to increase 
as a result of improved surveillance with imaging studies, 
including ultrasound and ultrasound-guided FNAB.11,26–29
We report the case of a BRAF-mutated lung adenocar-
cinoma with thyroid gland and bony metastases. Initially, 
both histological and molecular features suggested a thy-
roid origin, but further in-depth immunohistochemical and 
molecular analyses together with a multidisciplinary evalu-
ation led to the final diagnosis.
Our case is a stark example of tailored treatment that is 
based on the molecular features of the tumor. This involved 
a multigene approach that simultaneously investigated the 
mutational status of several genes, even those not deemed 
to be clinically relevant yet (ie, BRAF in lung cancer), 
and allowed for the identification of a druggable mutation 
whose inhibition led to a good clinical response. 
BRAF mutations are detected in ~2%–4% of lung 
cancers, occurring at a lower frequency than EGFR mutations 
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Figure 1 Thyroid surgical resection specimen. 
Notes: Napsin a-positive immunostaining with negative internal control of normal thyroid tissue (A), HTG-negative immunostaining of the tumor with positive internal 
control (B), and mass spectrometry diagram showing the presence of V600e mutation peak (arrow) (C). Lung biopsy: napsin a-positive immunostaining (D), HTG-negative 
immunostaining (E), and mass spectrometry diagram showing the presence of V600e mutation peak (arrow) (F). Magnification 10×.
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
8.
11
0.
10
4.
28
 o
n 
25
-N
ov
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2016:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5402
Gerratana et al
(10%–15%) and probably in a slightly smaller subpopulation 
than ALK rearrangements (3%–5%) in Caucasians. Addition-
ally, BRAF mutations are more frequent in adenocarcinoma 
than squamous-cell carcinoma,30 with V600E mutation being 
the most recurrent (55%).4,5,31 In a large series of 739 lung 
adenocarcinomas screened for BRAF mutations, Marchetti 
et al described 21 cases harboring V600E mutation that 
was mainly associated with female sex (9% vs 15%) and 
nonsmoker history (5% vs 2%).32 With an incidence of 
40%–45%,33–35 BRAF V600E mutation is also typically 
associated with papillary thyroid carcinoma.
In patients with advanced melanoma, BRAF V600 muta-
tions have been widely recognized as a valid predictive factor 
for treatment with BRAF inhibitors, namely vemurafenib 
and dabrafenib.36 Notably, in a recent basket trial, among 
19 patients with BRAF-mutated NSCLC who received a 
BRAF inhibitor, the objective response rate was 42%, the 
median progression-free survival was 7.3 months, and the 
median overall survival has not been reached yet.13 The occur-
rence of BRAF V600E mutation in a pulmonary neoplastic 
lesion of a patient with a previously resected papillary thyroid 
tumor evocated the hypothesis of a metastatic involvement 
of the lung, as previously reported in literature.37
The morphology pattern and molecular status alone 
could not distinguish whether the lung lesion was a primary 
or a secondary tumor. Based on an immunohistochemistry 
panel (PAX8, HTG, TTF1, CK7, napsin A), we avoided to 
consider the lung lesion as a metastatic deposit of the previ-
ously diagnosed thyroid papillary carcinoma.
To date, only one case of EGFR-mutated lung cancer with 
metastasis to thyroid gland has been reported. The patient 
was treated with erlotinib and had an excellent clinical and 
radiographic response. Another interesting case of tumor-to-
tumor metastasis has also been described in an 80-year-old 
female who had a papillary thyroid carcinoma with a BRAF 
V600E mutation that metastasized into an EGFR-mutated 
(L858R) lung adenocarcinoma.38
To the best of our knowledge, this is the first reported 
case of a BRAF V600E-mutated lung adenocarcinoma with 
metastasis to the thyroid gland and treated with dabrafenib. 
Furthermore, in the era of targeted therapy, our clinical 
case also emphasized the need to reconsider the criteria of 
radiological evaluation. The first tumor reassessment after 
dabrafenib initiation was classified as stable disease according 
to RECIST criteria; however, the patient experienced an 
overall clinical improvement mainly due to a radiologically 
documented initial regression of lymphangitis.
Based on the promising results obtained in recent basket 
trials, a multigene approach for all tumors might lead to new 
therapeutic options. Molecular pathology laboratories should 
Figure 2 serial imaging assessment of tumor.
Notes: at baseline (A), at progression to first line with carboplatin plus pemetrexed (B), and at first (C) and current evaluation after dabrafenib initiation (D).
Abbreviation: CT, computed tomography.
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be able to allow clinical use of multiple genetic information 
simultaneously, even in very small endoscopic and cytologi-
cal samples, with high analytical sensitivity. 
Disclosure
The authors report no conflicts of interest in this work.
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